Confluence Pharmaceuticals
Carmel, US · 3 known investors
Find your way into Confluence Pharmaceuticals
Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders. Its treatments target pediatric and adult patients, addressing symptoms such as communication, social behavior, attention, anxiety, and hyperactivity.
Founders & leadership
SL
Steven L. JohnsPresident & Founder
Board
BW
Boyd W. Sturdevant, Jr.Chairman & Founder
Investors · 3
Also in the syndicate · 1
IU Philanthropic Venture Fund
Funding
SEC filings, press & company announcements$1.3M disclosed across 2 of 4 rounds · 2016–2022
- Undisclosed amountSeries BJun 2022Source ↗
▶$10KraisedOct 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$10KraisedOct 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Phil LodatoDirector
- Steven L. JohnsExecutive Officer, Director
- Boyd W. Sturdevant, Jr.Director
- Offering amount
- $800K
- Amount sold
- $10K
- Minimum investment
- $10K
- First sale
- Sep 2018
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b
▶$1.3MraisedNov 2016 · 10 investors · PharmaceuticalsRule 506(c)
▶$1.3MraisedNov 2016 · 10 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Boyd W. Sturdevant, Jr.Director
- Steven L. JohnsExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Confluence Technologies4 shared keywordsConfluence provides data aggregation, analytics, and reporting solutions for investment consultants to analyze funds and deliver performance and risk insights to their clients.
Thumbnail for Seragon Pharmaceuticals4 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Aclaris Therapeutics3 shared keywordsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
Atlassian3 shared keywordsAtlassian offers a teamwork platform combining project planning, knowledge management, and AI orchestration tools for teams and their AI agents. Its products help organizations plan, execute, and deliver work at scale.
Circumvent3 shared keywordsCircumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.
Collegium Pharmaceutical3 shared keywordsCollegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Companies competing with Confluence Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Confluence Pharmaceuticals do?
- Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders. Its treatments target pediatric and adult patients, addressing symptoms such as communication, social behavior, attention, anxiety, and hyperactivity.
- Who are Confluence Pharmaceuticals's investors?
- Confluence Pharmaceuticals's investors include Elevate Ventures, IU Ventures.
- How much funding has Confluence Pharmaceuticals raised?
- Confluence Pharmaceuticals has disclosed $1.3M raised across 2 of its 4 known rounds.
- Where is Confluence Pharmaceuticals headquartered?
- Confluence Pharmaceuticals is headquartered in Carmel, US.